ADP-600 / Adaptimmune - LARVOL DELTA

Adaptimmune Reports Q2 2024 Financial and Business Updates (Adaptimmune Press Release) - "Adaptimmune Therapeutics plc...reports financial results and business updates for the second quarter ended June 30, 2024...Sarcoma centers of excellence across the Unites States are being onboarded as Authorized Treatment Centers (ATCs) for Tecelra...Uza-cel is being investigated in the SURPASS-3 Phase 2 clinical trial (NCT05601752) for the treatment of platinum-resistant ovarian cancer...The SURPASS-3 trial is currently enrolling patients; Screening in the SURPASS Phase 1 trial has stopped and enrolment will cease shortly....IND-enabling activities continue for ADP-600 (PRAME) and ADP-520 (CD70) programs."

Commercial • Enrollment status • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Synovial Sarcoma

Development and Preclinical Characterization of an Engineered T-Cell Therapy Targeting PRAME-Expressing Solid Tumors (ASGCT 2024) - "PRAME is an attractive target for adoptive T-cell therapy using affinity-enhanced TCRs. We have generated and characterized an affinity-enhanced TCR and subjected it to our extensive preclinical testing package, where it demonstrated potency toward PRAME-positive tumor targets while maintaining stringent specificity. These data describing ADP-600 may be used to support an investigational new drug application to enable the use of this product in clinical trials."

IO biomarker • Preclinical • Breast Cancer • Endometrial Cancer • Genetic Disorders • Hematological Malignancies • Leukemia • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Synovial Sarcoma • Triple Negative Breast Cancer • Uterine Cancer • GZMB • HLA-A • IFNG • PRAME

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Adaptimmune Press Release) - "Adaptimmune Therapeutics plc...provides a progress update on its PRAME program (ADP-600)....'ADP-600 exhibits excellent potency and safety in preclinical assessments, and we plan to move this TCR into the clinic in 2024'....The first-generation clinical candidate, designated ADP-600, was identified through Adaptimmune's proprietary preclinical testing program to investigate the safety, specificity and potency of T-cells expressing engineered T-cell receptors (TCRs). This will support an IND submission to progress the Company's PRAME program to an initial Phase 1 clinical trial to evaluate the safety of ADP-600 in multiple tumor types....This program complements the Company's existing validated clinical programs with MAGE-A4 and more information will be available on the program in 2024."

IND • New molecule • New P1 trial • Oncology • Solid Tumor